Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published April 11, 2017 | Published + Supplemental Material
Journal Article Open

Identification of targets of tumor suppressor microRNA-34a using a reporter library system

Abstract

miRNAs play critical roles in various biological processes by targeting specific mRNAs. Current approaches to identifying miRNA targets are insufficient for elucidation of a miRNA regulatory network. Here, we created a cell-based screening system using a luciferase reporter library composed of 4,891 full-length cDNAs, each of which was integrated into the 3′ UTR of a luciferase gene. Using this reporter library system, we conducted a screening for targets of miR-34a, a tumor-suppressor miRNA. We identified both previously characterized and previously uncharacterized targets. miR-34a overexpression in MDA-MB-231 breast cancer cells repressed the expression of these previously unrecognized targets. Among these targets, GFRA3 is crucial for MDA-MB-231 cell growth, and its expression correlated with the overall survival of patients with breast cancer. Furthermore, GFRA3 was found to be directly regulated by miR-34a via its coding region. These data show that this system is useful for elucidating miRNA functions and networks.

Additional Information

© 2017 National Academy of Sciences. Edited by Tak W. Mak, The Campbell Family Institute for Breast Cancer Research at Princess Margaret Cancer Centre, University Health Network, Toronto, Canada, and approved March 9, 2017 (received for review December 8, 2016). Published online before print March 29, 2017. We thank Drs. Akio Yamashita, Masato Yano, Tomoaki Tanaka, and Kazuhiko Kuwahara for helpful discussions and Mayuko Yoda, Yukinari Osaka, Nobuhiro Yamamoto, and Ayaka Ichise for technical assistance. This work was supported by Core Research for the Evolutionary Science and Technology (CREST) funding from the Japan Science and Technology Agency; CREST funding from the Japan Agency for Medical Research and Development; Grants-in-Aid for Scientific Research (KAKENHI) Grants 26113008, 15H02560, 15K15544, 15K15026, and 25860139 from the Japan Society for the Promotion of Science; NIH Grants AR050631 and AR065379; the Naito Foundation; and a Bristol-Myers K.K. RA Clinical Investigation Grant. Author contributions: Y.I., A. Inoue, and H.A. designed research; Y.I., A. Inoue, T.S., Y.H., A. Igarashi, and T.T. performed research; Y.I., A. Inoue, and H.A. contributed new reagents/analytic tools; Y.I., A. Inoue, T.S., Y.H., T.T., K.D.T., M.P.B., and H.A. analyzed data; and Y.I. and H.A. wrote the paper. The authors declare no conflict of interest. This article is a PNAS Direct Submission. This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1620019114/-/DCSupplemental.

Attached Files

Published - PNAS-2017-Ito-3927-32.pdf

Supplemental Material - pnas.1620019114.sd01.xlsx

Supplemental Material - pnas.201620019SI.pdf

Files

PNAS-2017-Ito-3927-32.pdf
Files (7.2 MB)
Name Size Download all
md5:22d48707fce9eef00e42ff56af21b194
283.4 kB Download
md5:c2551daad46c9d13076b9e19407c6c87
1.7 MB Preview Download
md5:b9135cd39fb9c343a805069fb02d0bea
5.2 MB Preview Download

Additional details

Created:
August 21, 2023
Modified:
October 25, 2023